Identifying hits in phenotypic studies using artificial intelligence based morphological analysis

How are biotechs and big pharma companies using artificial intelligence to improve hit identification in high - throughput screening?

In high-content, high-throughput screening, identifying true hits requires more than just signal detection – it requires understanding morphological effects and ensuring data quality. This case study outlines how pharmaceutical and biotechnology customers have used Ardigen’s phenAID platform to improve hit identification using AI and advanced phenotypic profiling.

The Challenge

  • Detecting true phenotypic hits among thousands of tested compounds.
  • Filtering out toxicity-driven signals that distort biological relevance.
  • Linking morphological changes to both chemical and genetic perturbations.
  • Identifying quality issues in large-scale screens.

Our Approach

Using the Hit Identification module of phenAID, Ardigen:

  • Analyzed imaging data with a combination of CellProfiler and deep learning features.
  • Cross-referenced results with positive and negative controls.
  • Flagged samples with abnormal quality metrics for rerun.
  • Separated toxicity-related effects from relevant phenotypes.
  • Linked morphological features to known chemical and genetic perturbations.

Ardigen phenAID platform module for Hit Identification guides the research phase of a biotech company.

Ardigen’s phenAID streamlined the client’s hit identification process, delivering accurate, interpretable, and actionable results. This not only saved time but ensured that downstream decisions were based on robust, AI-supported insights.

Results

  • Interpretable hits with visual confirmation of key phenotype-driving features.
  • Quality control alerts triggered second screening runs where needed.
  • Customized filtering improved biological relevance of selected hits.
  • Enabled deeper insight into the relationship between compound action and phenotype.

Ardigen’s phenAID streamlined the client’s hit identification process, delivering accurate, interpretable, and actionable results. This not only saved time but ensured that downstream decisions were based on robust, AI-supported insights.

Expert Contribution

The precision and interpretability of these results are a testament to the expertise of our team, including Nasim Jamali, Senior Bioinformatician at Ardigen.

Nasim specializes in data analysis and visualization of complex biological data, including NGS and omics, and her contributions ensure our AI-supported insights are both robust and actionable.

Further Reading from Ardigen's Knowledge Hub

Want to achieve similar efficiency gains? Let's discuss how we can optimize your project.

You might be also interested in:

Scientist analyzing high-content cell images on a computer screen – visualizing AI-driven phenotypic profiling in drug discovery.
The Future of Drug Discovery: Integrating Phenotypic Data with Omics and AI
AI-driven target identification process in drug discovery.
a biopharma lab
What’s trending in European Biopharma? A look ahead

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!